Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Rosetta and NYU School of Medicine collaborate on screening microRNA biomarkers for CHD

Rosetta Genomics : 22 November, 2007  (New Product)
Rosetta Genomics and NYU School of Medicine have expanded their collaboration to include congenital heart disease (CHD).
Applying Rosetta Genomics innovative microRNA extraction protocols from various body fluids and NYU School of Medicine's vast experience in this field, this collaboration will screen for specific microRNA biomarkers and signatures that may be used to diagnose and target congenital heart disease in newborns.

About 40,000 infants (1 out of every 125) are born with CHD each year in the USA. The defect may be minor and the baby appears healthy for many years after birth, or severe enough that the baby's life is in immediate danger. CHD is caused by the improper development of the heart or blood vessels near the heart, causing abnormal flow of blood. These abnormalities can result in congestive heart failure, pulmonary hypertension, and arrhythmias, with severe impairment of growth and development.

Recent studies have revealed key roles of microRNAs as regulators of growth, development, function, and responses to stress in the heart. We believe that these recently discovered regulatory mechanisms may serve as potential diagnostic biomarkers and therapeutic targets for the treatment of heart disease.

'We have recently put in place a robust diagnostic development engine that includes hundreds of microRNA biomarkers and proprietary technologies,' noted Amir Avniel, CEO and president of Rosetta Genomics. 'This engine is what allows us to rapidly expand our pipeline. As a cutting edge research institution, NYU School of Medicine is a close collaborator of Rosetta Genomics in the microRNA field, and I am confident this collaboration will enhance our understanding of the link between microRNAs and various heart conditions.'

'It is now clear that microRNAs play a key role in controlling diverse aspects of cardiac development and response to disease,' noted Dr David B. Meyer, director of Pediatric and Congenital Cardiothoracic Surgery, at NYU School of Medicine. 'Rosetta Genomics' extensive knowledge and proprietary technologies in the microRNA field, coupled with our experience in CHD, is an excellent starting point for this collaboration.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo